Tislelizumab and Chemotherapy Approved as First-line Option for Stomach and Gastroesophageal Junction Cancers
The FDA has approved tislelizumab plus chemotherapy for certain patients with gastric or gastroesophageal junction adenocarcinoma. The U.S. Food...